ACE2 and COVID-19: In particular, the class of anti-TNFα antibodies, mostly used for the treatment of inflammatory rheumatic diseases, could be able to challenge COVID-19 by two main actions: the classical TNFα inhibition and a down-regulation of ACE2 expression resulting in decreased binding sites for SARS-CoV-2 [72, 73].